Prognostic Value of Long Non-Coding RNAs GUSB Pseudogene 11 in Colorectal Cancer and Its Regulatory Effect on Tumor Progression

TL;DR

This study explores how the lncRNA GUSBP11 affects colorectal cancer progression and prognosis by regulating miR-605-3p.

Contribution

The novel contribution is identifying GUSBP11's regulatory role in CRC through miR-605-3p and its impact on tumor progression.

Findings

GUSBP11 is upregulated in colorectal cancer and linked to worse prognosis.

Silencing GUSBP11 inhibits cancer cell proliferation, migration, and invasion.

miR-605-3p is a downstream target of GUSBP11 and negatively regulated by it.

Abstract

Colorectal cancer (CRC) is the third most common cancer, and its progression to advanced diagnosis leads to a dismal prognosis. The long non-coding RNA (lncRNA) GUSB Pseudogene 11 (GUSBP11) can act in a variety of cancers. Nevertheless, the potential mechanism of GUSBP11 in CRC has not been reported. The purpose of this study is to investigate the relationship between the role of GUSBP11 expression in CRC progression as well as prognosis.

Two hundred and fifty-nine CRC patients were recruited. Expression levels of GUSBP11 and downstream target genes in CRC cell lines were evaluated by quantitative reverse transcription polymerase chain reaction. The influence of clinical characteristics and GUSBP11 on prognosis was evaluated by the proportional hazards model. Cell-Counting-Kit-8 and transwell assays were conducted for detection of CRC cell proliferation, migration, and invasion. Dual luciferase and correlation analyses were used to validate GUSBP11 with predicted genes. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed to analyze downstream gene function and signaling pathways.

The expression of GUSBP11 was upregulated in CRC and relevant to the deterioration of prognosis. The CRC cell proliferation, migration, and invasion were inhibited by GUSBP11 silencing. miR-605-3p was the downstream target gene of GUSBP11, and its expression is negatively regulated by GUSBP11.

Taken together, this study highlights that the inhibition of miR-605-3p by GUSBP11 to regulate the downstream signaling pathway leads to prognostic malignancy and promotes tumor growth in CRC.

Figures